PYRAMID-ANALYTICS
16.6.2022 09:02:14 CEST | Business Wire | Press release
BIG DATA ANALYTICS CONFERENCE – Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, announced today that Tom Warren has been appointed Regional Managing Director, UK and Ireland (UKI). Warren brings with him twelve years of experience leading high achieving teams, alongside his previous experience as a professional rugby player, to build upon Pyramid’s growth in the UKI. The company’s customers in the UKI include Ann Summers, Liberty London, and Premier Foods.
The appointment follows Pyramid Analytics’ recent oversubscribed US $120MM Series E funding round, which was announced at a special event on May 9 from Tower Bridge in London. Pyramid is doubling down on its investment in the UKI, a leading market for decision intelligence adoption. In 2022, the UK tech ecosystem hit a landmark valuation of $1 trillion . At the centre of this tech success story is London. Pyramid plans to double its headcount in London over the coming months, to then use London as a base to support its European expansion. The appointment of Warren highlights Pyramid’s commitment to, and ambitions for, the UK and Ireland.
Key Points:
- Pyramid Analytics, a decision intelligence platform provider, hires experienced technology sector leader Tom Warren to accelerate UKI growth. Warren has twelve years leading successful teams and customer relationship management.
- Pyramid expanding investment in UKI talent, sales and marketing, and partner expansion.
- Warren’s appointment is the first in a series of planned business development initiatives to support customer success and strategic accounts in this region.
- Click here to schedule a demo of the Pyramid Decision Intelligence Platform .
Warren’s remit is to build out the UK and Ireland business, which will involve enterprise sales, business development, and channel and solutions engineering functions. Having started his career as a professional rugby player, Tom Warren is excited about the challenge ahead.
Meet our new Managing Director
Warren had a successful career as a professional rugby player for Worcester Warriors , London Irish , Grand Parma in Italy and finally at Esher RFC . This included a Division 1 title for Worcester in 2004 and playing in an English Premiership semi-final and European Challenge Cup final for London Irish in 2006. After his retirement, Warren initially turned his hand to coaching as the Scrum Coach and Director of the Academy at Esher.
Since then, he has had a successful career in sales. His most recent role was as Area VP Northern Europe at the cloud-based logistics platform Bringg where he was responsible for building out the EMEA sales team. In a previous role as Senior Director for EMEA Enterprise renewals at Blue Prism, he successfully increased customer renewals from 82% to 88%, which accounted for a 113% increase in the 2019 financial year. He was also Regional Sales Director at ServiceNow, where he set up the first UK Commercial sales team and consistently exceeded targets for delivering new business to help grow the UK business.
Decision Intelligence is the Next Big Data Analytics Innovation
The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.
The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
Quotes
Omri Kohl, Chief Executive Officer and Co-Founder, Pyramid Analytics: “Tom has brought a vast wealth of expertise and insight to the Managing Director role. He has a strong history of leading impressively successful sales and customer relationship teams and has helped multiple companies expand their sales outreach into the EMEA region.
“As a former professional rugby player and with over twelve years of heading sales teams, we knew that Tom would bring strong leadership skills, courage and energy to our growing team here at Pyramid. We believe that Tom is the right individual to lead our already high performing team to continue our growth in the UK and Ireland, following our phenomenal Series E funding round performance.”
Tom Warren , Regional Managing Director, UKI, Pyramid Analytics : “Pyramid is what’s next in analytics and the UK is what’s next for Pyramid. I am really excited to be joining Pyramid Analytics and even more so to be joining a successful and high performing team, which has been behind their expansion in the UK and Ireland.
“Our Series E funding round earlier this month was a real statement of intent from the company, showcasing our ambition to expand our UK and Ireland operations so that Decision Intelligence can continue to transform the way businesses operate in the region. I look forward to contributing to this great company and working towards our European expansion.”
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for everyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo .
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners , Jerusalem Venture Partners (JVP), Sequoia Capital , and Viola Growth . Learn more at Pyramid Analytics .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005248/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom